FDA Approves Pembrolizumab for HER2 Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma Expressing PD-L1 (CPS ≥1) By Ogkologos - April 11, 2025 430 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the KEYNOTE-811 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR First New Drug in Years Reduces Recurrence in High-risk Hormone Receptor... September 20, 2020 Reunión anual de la American Society of Clinical Oncology de 2022:... June 7, 2022 ESMO Highlights Key Issues for Patients with Cancer and Their Carers... May 27, 2025 Home Is Where the Heart Is November 8, 2019 Load more HOT NEWS Mutational Patterns Drive Metastatic Aggressiveness of Appendiceal Adenocarcinomas Darolutamide Extends Survival for Some People with Metastatic Prostate Cancer Opinion: ‘We need to increase testing in primary care’ Trial Highlights Complexities of Targeted Therapy for Pancreatic Cancer
